See the DrugPatentWatch profile for Bictegravir
What does a Paragraph IV filing mean for bictegravir?
A Paragraph IV filing is an application by a generic (or biosimilar) drug company asserting that a listed patent for the branded product is either invalid, unenforceable, or would not be infringed by the generic version. This is part of the FDA’s Abbreviated New Drug Application (ANDA) process for small-molecule generics.
Where does bictegravir fit?
Bictegravir is an HIV integrase inhibitor. If a company files a Paragraph IV ANDA to seek approval for a generic bictegravir product, the filing signals that it is challenging one or more patents protecting the branded bictegravir formulation (or its combination product, depending on what is being pursued). The key practical effect is that it can trigger patent litigation and can affect when FDA approval (and market entry) can occur.
What happens after a Paragraph IV filing?
After a Paragraph IV ANDA submission for bictegravir (or any other drug), the branded patent holder and the generic filer typically exchange notices and may go to court. The timing and outcome of that litigation can determine whether the generic product can launch when FDA otherwise approves it.
How long until a bictegravir generic can launch?
The launch timeline depends on:
- Whether FDA grants approval after the ANDA review.
- Whether there is patent litigation and what the court decides.
- The presence of any exclusivity or blocking periods that can pause or delay approval/marketing.
Because specific dates depend on the exact bictegravir product, the patents listed in the FDA Orange Book, and the litigation posture, the most reliable way to answer “when” for a particular bictegravir Paragraph IV filing is to identify the specific ANDA and the specific branded reference product it cites.
What details should you look for in a specific bictegravir Paragraph IV filing?
For any given bictegravir Paragraph IV filing, the most useful search targets are:
- The ANDA number (and the applicant name).
- The branded reference listed drug (RLD) for which patents are being challenged.
- The Orange Book patents asserted in the notice (so you know what is being attacked).
- Whether the filing is for bictegravir alone or a combination product, since that changes which patents matter.
- Any court case docket information tied to the notice.
Can you share the exact bictegravir product or applicant name?
If you provide the branded drug name the ANDA references (for example, which bictegravir-based fixed-dose combination) or the applicant/ANDA number, I can narrow the answer to that specific Paragraph IV filing’s likely patent issues and the typical regulatory/litigation consequences that follow.
Sources
No sources were provided with the request, and no external materials were included for citation.